Anxiety, Menopause
Conditions
Brief summary
Symptoms of anxiety are prevalent during the menopausal transition and early postmenopause. These symptoms are mainly improved by anti-anxiety agents, which are associated with some adverse effects including dizziness, sleepiness, and constipation and not all patients respond to currently available pharmacological treatments, thus novel agents with fewer side effects are needed. Some studies have shown that traditional Chinese medicine can alleviate menopausal symptoms safely and economically, and improve quality of life. Xiangshao granules reportedly have good curative effects on menopausal symptoms and premenstrual syndrome and exhibit good safety. This study aim to evaluate the efficacy and safety of Xiangshao granule in improving anxiety state of women with menopause syndrome.
Interventions
dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
DRUGXiangshao Granules Placebo
Xiangshao Granules Placebo
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* meet the diagnostic criteria for menopause syndrome (age 40-65 years, being in the menopausal transition stage or postmenopausal stage determined according to the 2011 Stages of Reproductive Aging Workshop +10 criteria). * 50 ≤ SAS scores ≤ 69. * improved Kupperman scores ≥16. * has an intact uterus and at least one ovary. * able and willing to participate in study and provide written informed consent, and agrees to follow all study requirements. The investigator consider the subject able to complete the study.
Exclusion criteria
* history of allergy or sensitivity to investigational product. * currently or historically taking medication or psychotherapy for menopause anxiety in the past 4 weeks, including but not limited to estrogens, oestrogen-like hormone, Chinese medicine or health care products used to relieve anxiety (such as soy isoflavones, vitamin E, black cohosh), anti-anxiety agents, antidepressants, mood stabilizers, sedatives. * anxiety or other psychiatric disease unrelated to menopause (eg., currently or previously diagnosed as major depression, acute panic disorder, obsessive-compulsive disorder, phobia, hypochondria, mood disorder or schizophrenia or psychiatric diseases caused by other psychoactive substances or organic diseases), anxiety symptoms caused by stress, suicidal tendency, alcohol or drug dependence, etc. * having major depression as defined by a SDS score≥70 at screening. * systemic disease (eg., hypothyroidism/hyperthyroidism, unstable coronary heart disease, severe hypertension \[sbp≥180mmHg and/or dbp≥110mmHg\] or pheochromocytoma). * definite diagnosis of endometrial cancer, cervical cancer, ovarian cancer and other gynecological malignancies, as well as breast cancer. * severe liver or kidney diseases (eg., alanine aminotransferase\[ALT\]/aspartate aminotransferase\[AST\]/serum creatinine\[Scr\] levels 2 times greater than the upper limit of normal) or severe primary diseases in cardiovascular, cerebrovascular, liver, kidney and hematopoietic system. * participated in other clinical trials within the last 3 months. * lactating or pregnant women, or plan to become pregnant during study or not agree to use reliable contraceptive methods throughout the study period. * other reasons the investigator consider the patient may not be suitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-rating Anxiety Scale (SAS) scores change (%) | 8 weeks | % change in SAS scores after 8 weeks of treatment compared with baseline scores |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kupperman scores change (%) | 4 weeks | % change in Kupperman scores after 4 weeks of treatment compared with baseline scores |
| Self-rating Depression Scale (SDS) scores change (%) | 4 weeks | % change in SDS scores after 4 weeks of treatment compared with baseline scores |
| SDS scores change (%) | 8 weeks | % change in SDS scores after 8 weeks of treatment compared with baseline scores |
| SAS scores change (%) | 4 weeks | % change in SAS scores after 4 weeks of treatment compared with baseline scores |
| serum FSH level | 8 weeks | change in serum FSH level after 8 weeks of treatment compared with baseline |
| serum estradiol (E2) level | 4 weeks | change in serum estradiol(E2) level after 4 weeks of treatment compared with baseline |
| gastrointestinal symptom score (GIS) change (%) | 4 weeks | % change in GIS after 4 weeks of treatment compared with baseline scores |
| serum Follicle Stimulating Hormone (FSH) level | 4 weeks | change in serum FSH level after 4 weeks of treatment compared with baseline |
Countries
China
Outcome results
None listed